HIND Stock Analysis: Buy, Sell, or Hold?
HIND - Vyome Holdings, Inc. Common Stock
$1.92
-0.22 (-10.28%)
▼
WAIT
LOW Confidence
Last Updated: January 30, 2026
Get Alerted When HIND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called HIND this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: HIND is down 39.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: HIND is down 39.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: HIND is currently trading at $1.92, which is considered oversold relative to its 30-day fair value range of $2.83 to $3.59.
Technical Outlook: Technically, HIND is in a strong downtrend. The price is currently testing key support at $1.87. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+600.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HIND is in a strong downtrend. The price is currently testing key support at $1.87. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+600.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.83 -
$3.59
Company Quality Score
45/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
72.1%
Protect Your Profits
Holding HIND? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BEARISH: Downward momentum (-10.3%)
- BULLISH: Trading 600.9% below Wall St target ($15.00)
- WARNING: Recommendation downgraded due to -39.8% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$2.83 -
$3.59
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.87
Resistance Level
$3.89
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-4.76
Wall Street Target
$15.00
(+600.9%)
Revenue Growth (YoY)
46.9%
Last updated: January 31, 2026 1:01 AM ET
Data refreshes hourly during market hours. Next update: 2:01 AM
Data refreshes hourly during market hours. Next update: 2:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HIND showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 59 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$141 | 59 HOLD |
Advanced HIND Option Strategies
Professional options setups generated by AI based on today's HIND price and gamma walls.